Welcome to our dedicated page for BNB Plus news (Ticker: BNBX), a resource for investors and traders seeking the latest updates and insights on BNB Plus stock.
BNB Plus Corp. reports developments across its BNB digital-asset treasury strategy and its LineaRx biopharmaceutical manufacturing subsidiary. Company updates include BNB token treasury management, DeFi-oriented yield generation, Nasdaq issuer matters, governance changes, investor communications, material agreements, and operating results.
LineaRx news centers on the LineaDNA cell-free DNA production platform, large-scale DNA manufacturing orders, supply activity for diagnostic and genetic-medicine customers, and intellectual property tied to the Linea IVT platform and Linea RNAP enzyme. The company’s disclosures also reflect its history as Applied DNA Sciences and its continuing use of enzymatic DNA production technologies within the LineaRx business.
BNB Plus Corp. (OTCQB: BNBX) announced it has mutually agreed with Cypress Management to end their advisory and asset management arrangement and will now execute its BNB digital asset treasury strategy fully in-house. According to BNB Plus, this follows a recent shareholder-led financing and is intended to better align treasury strategy and execution as part of its ongoing strategic review. Further details are provided in its Form 8-K filed July 29, 2026.
BNB Plus Corp. (Nasdaq: BNBX) reported that a Nasdaq Hearing Panel has issued a delisting determination due to the company’s non-compliance with the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). Trading of BNB Plus common stock on Nasdaq will be suspended at the open on July 14, 2026.
The company plans to request a review of the decision by the Nasdaq Listing and Hearing Review Council, which may affirm, modify, reverse, or remand the Panel’s decision, though the request will not stay the delisting. BNB Plus has secured approval for quotation on the OTCQB Venture Market under the symbol BNBX, where trading is expected to begin on July 14, 2026 or as soon as possible thereafter. According to BNB Plus, it expects no impact on business operations and will remain a fully reporting SEC registrant, but there is no assurance the review will restore Nasdaq listing.
BNB Plus (Nasdaq: BNBX) secured initial commitments for $4.1M of convertible preferred stock financing, targeting $5.0M in total proceeds. Funds will bolster its digital asset treasury and support a strategic review of its digital asset and biotechnology businesses.
According to the company, pro forma cash and digital assets are expected to exceed $16.4M. The financing includes Series B-1 and B-2 preferred stock with dividends of 8.0% and 6.0%, liquidation preferences up to 1.5x, and attached warrants. GlobalStake will advise on the strategic review, including potential monetization of LineaRx.
BNB Plus (NASDAQ: BNBX) announced LineaRx completed its largest LineaDNA order: $1.2 million with shipments finishing in early May 2026. Production ran at historically higher margins with zero batch failures and a new cadence record of more than 1.5 grams per week.
The Board has authorized a formal strategic alternatives review; no assurance a transaction will occur or be disclosed.
BNB Plus Corp (Nasdaq: BNBX) announced a Board-authorized review of strategic alternatives to maximize shareholder value and provided a Nasdaq listing status update. As of 1pm ET on April 18, 2026, the treasury was valued at $12.2 million, about 3.4x its market cap.
The review may include mergers, acquisitions, asset sales, capital raises and other transactions. The company implemented an active yield-generation strategy on its BNB holdings and retained Lucid Capital Markets as financial advisor. Nasdaq notified the company on March 20, 2026 of a $1.00 bid-price deficiency; a hearing has been requested.
BNB Plus (Nasdaq: BNBX) announced a European patent grant from the EPO for compositions and methods covering its chemically modified Linea RNAP, a core enzyme in the Linea™ IVT platform. The grant follows a U.S. patent in 2024 and the company plans to validate protection in key European markets through at least 2040.
The technology was acquired via the Spindle Bio acquisition in July 2023 and the company said the patent strengthens IP and potential monetization for mRNA manufacturing customers.
BNB Plus Corp (Nasdaq: BNBX) said LineaRx received two new LineaDNA orders from established genetic medicine developers, with production and shipment expected before June 2026. LineaRx recorded a $1.2 million accelerated order—the largest to date—and expects to ship over $1.5 million of LineaDNA in H1 2026, including ~8 grams this quarter.
The company implemented cost reductions delivering ~$3 million annual savings plus >$600,000 from a smaller headquarters move. BNBX also holds BNB tokens and OBNB trust units valued at >$10.7 million at $598/token as of Feb 23, 2026, reportedly more than double its market cap.
BNB Plus (Nasdaq: BNBX) appointed James Haft as an Independent Director effective February 2, 2026. Haft brings 35+ years in digital assets, blockchain infrastructure, emerging markets and capital markets, and will join the Board’s Nominating Committee to support BNB treasury operations and DeFi yield initiatives.
His background includes leadership roles at Bear Stearns, ING Barings, founding PALcapital, co-founding CryptoMondays and chairing the first publicly listed Web3 company on the Oslo Stock Exchange.
BNB Plus Corp (NASDAQ: BNBX) will present at the Digital Asset Virtual Investor Conference on January 27, 2026 at 1:00 PM EST. Chief Investment Officer Patrick Horsman, CFA, and Chairman Joshua Kruger will deliver a live presentation and be available for 1x1 meetings Jan 27–29, 2026. The event is an interactive online webcast with live Q&A and an archived replay available afterwards. Attendees are recommended to pre-register and run the system check to ensure participation. Registration and 1x1 scheduling are available via VirtualInvestorConferences.com.
BNB Plus (NASDAQ: BNBX) received a $1.2M accelerated order for LineaDNA, the largest LineaDNA order in company history.
The order accelerates an existing customer's two-year purchasing cadence into a delivery schedule expected to be completed by May 2026, and follows a prior $600,000 follow-on order from July 2025. Inclusive of the new order, the company expects to ship over $1.5M of LineaDNA to IVD and biotherapeutic customers in 1H CY2026. The announcement builds on recent fulfillment, including a LineaDNA shipment valued at over $390,000.